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We have examined 221 cases of mycoplasmal pneumonia in adults during the past 17 years.
During this time epidemic waves occurred every three to four years. The incidence of disease
was highest in patients 20 to 30 years of age. The most comon clinical features were cough,
fever, sputum, and rales. The most characteristic feature was a persistent cough which lasted
about three to four weeks. Roentgenographic examinations showed a variety of patterns, but
the most consistent feature was a feathery shadow, appearing in the lower field of either or
both of the lungs. Lung function tests showed peripheral airway impairment. Although roent-
genographic examination provided useful information, it could not be used as a pathognomic
feature of mycoplasmal pneumonia. Tetracyclines were most effective for eliminating clinical
symptoms, whereas the macrolides provided the best response based on roentgenographic
evaluations.
INTRODUCTION
Mycoplasma pneumoniae causes primary atypical pneumonia and upper
respiratory disease in young and adolescent children and in young adults [1,2,3,4].
Although mycoplasmal pneumoniagenerally follows a mild course, severe clinical
symptoms may occur. In some patients, infection produces high fever and a persis-
tent cough, and the agent may reside in the respiratory tract for a long period of
time. Secondary bacterial pneumonia and exacerbations of chronic respiratory
disease may occur or sequelae such as central nervous system disturbances, car-
diovascular diseases, and hepatitis may be seen in spite of the administration of ef-
fective antibiotics [2,3,4,5].
This paper reviews the epidemiology, clinical manifestations, and complicating
features ofthe disease, the roentgenographic, microbiologic, and serologic findings,
and the results of chemotherapy obtained in 221 adults with mycoplasmal
pneumonia.
MATERIALS AND METHODS
We have examined 605 cases of atypical pneumonia in adults during the period
ranging from 1965 through 1981 at the University Hospital, Nagasaki University
School of Medicine. Of these, 221 (36.5 percent) were diagnosed as having
mycoplasmal pneumonia and were selected for study on the basis of physical ex-
amination (clinical signs and symptoms), and by positive microbiological, serologic,
chest X-ray, and pulmonary function test findings. Of 221 patients studied, 105
(47.5 percent) were diagnosed by positive M. pneumoniae cultures, and the remain-
505
Address reprint requests to: Kinichi Izumikawa, M.D., Second Dept. of Internial Medicine, Nagasaki
University School of Medicine, 7-1, Sakamoto-maclli, Nagasaki city, Japan 852
Copyright ¢ 1983 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.TABLE 1
Clinical Effects of Antibiotics in Mycoplasmal Pneumonia, 414 Cases, Including Cases in Children
Doses (in Adults)
Mean Duration Mean Duration
Amount of Doses per No. of No. of of Fever of Cough
Antibiotics Dose Day Days Cases (days) (days)
Macrolides 200-400 mg 3 7-14 218 2.6 10.2
Tetracyclines 500 mga 3 7-14 52 2.3 9.0
Aminoglycosides b 1 4-7 13 3.2 9.0
Penicillins 1-2 g 3-4 4-7 28 4.8 10.5
Cephemes 1-2 g 1-2 4-7 83 5.5 9.9
Chloramphenicol 1-2 g 3-4 7-14 10 5.0 8.0
Non-treatment - - - 10 5.8 15.7
aDoxycycline, 100-200 mg, once a day, 7-14 days
bGM, 40-80 mg; DKB, 100-200 mg; SM and KM, 1-2 g
ing patients had fourfold or greater rises in specific, complement fixation antibody
titers. Procedures used for isolation [6], complement-fixation [6], chest X-ray [6],
and pulmonary function tests [7] have been reported previously. In brief,
oropharyngeal swabs were inoculated directly onto agar and also into broth media
[8]. Broth cultures were subcultured to agar medium following the first signs of
growth or at weekly intervals for two weeks. Agar cultures were observed periodi-
cally for development of typical colonies and identification of M. pneumoniae was
determined by the growth (disc) inhibition test [9]. Blood was obtained during the
acute and convalescent stages of infection, and serum was tested for the presence of
specific antibody by the complement-fixation test. Front and lateral chest X-rays
were taken during the initial examination and evaluated for the appearance and
location ofpulmonary disease in a blind manner by five different pulmonary disease
specialists. Pulmonary function tests were performed on 17 patients during the acute
and convalescent stages using a flow curve recorder. The antibiotic therapy regimen
used is given in Table 1.
RESULTS
Patients, Age and Sex
The age of the patients ranged from 15 to 82 years. One hundred sixty-five pa-
tients (74.6 percent) were less than 40 years old, and only nine cases (4.0 percent)
more than 60 years old; 107 of the patients were men and 114 were women.
Incidence ofDisease
Although respiratory tract infections have been reported to be more prevalent
during the fall and winter months [10], our study showed no significant seasonal
variation. The time of the peak incidence of mycoplasmal pneumonia varied with
the geographic location. Epidemics generally lasted from six to eight months. In
Nagasaki city, periodic outbreaks occurred in 1966, 1970, 1973, 1975-1976, and 1980;
the peak incidence of hospitalized patients occurred between January and August,
1980. In Sasebo, the peak incidence occurred between November 1976 and March
1977, and from February to December 1980, and in Fukue, from January to July,
1980.
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Clinical Findings
The clinical signs and symptoms of patients with mycoplasmal and non-
mycoplasmal pneumonia are shown in Fig. 1. All patients with mycoplasmal
pneumonia produced a characteristic cough which was particularly severe at night
and often persisted for three to four weeks, even after the resolution of abnormal
roentgenographic findings. Fever (>37°C) was present in 207 patients (93.7
percent); 45.3 percent had fever greater than 39°C, and 76.4 percent had fever about
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FIG. 1. Signs and symptoms of adult patients with mycoplasmal pneumonia.IZUMIKAWA AND HARA
38°C. Sputum was ejected in 70.5 percent of the patients, dry or moist rales were
found in 66 percent, headache developed in 62 percent, dyspnea was present in 22
percent, and chest pain was described in 30 percent ofthe cases. Although myringitis
has been associated [11] with mycoplasmal pneumonia in children, it was present in
only 5 percent of our adult patients. Thus, the salient features of mycoplasmal
pneumonia in our study were a cough, sputum ejection, fever, and headache. Co-
ryza, chest discomfort, sore throat, and arthralgia were characteristic of atypical
pneumonias of other etiology.
Laboratory Studies
Leucocyte counts remained within the normal range in most cases (60 percent) but
leucophilia (13 percent) occurred in some. However an increased erythrocyte
sedimentation rate was seen in 64 percent and C-reactive protein was positive in ap-
proximately 90 percent of the cases.
Roentgenographic Findings
The Brolin classification of disease was used to evaluate the chest X-ray patterns
in the study group. Fifty-two percent of the patients showed an alveolar pattern, 9
percent an interstitial pattern, and 29 percent had a mixed alveolar and interstitial
pattern on initial examination. Seventeen cases (8.3 percent) developed pleural effu-
sion and three cases had atelectatic changes. Patterns of disease were most com-
monly seen in the lower lung fields. The right lung lower field was most commonly
involved, followed by the left lower field and then the middle field. Frontal and
lateral chest X-ray examination revealed a preferential occurrence in region seg-
ments 3, 4, 5, 8, and 10 on the right side lung and region segments 3 and 10 on the
left side. Forty-five cases (20 percent) had bilateral abnormalities.
Lung Function
The lung function tests were performed during the acute and convalescent stages
of disease in 17 adult patients (seven men and ten women) with acute mycoplasmal
pneumonia. The forced expiratory volumes per second percent (FEV 1.0 percent)
during the acute stage were decreased in 15 of 17 cases, and six of the cases had a
severe decrease in FEV of 1.0 percent. The V75/HT and V50/HT values were also
reduced during the acute stage but showed quick recoveries after treatment. The
V25/HT values of all patients examined on admission were lower than the predicted
values. Based on follow-up studies of V25/HT values, impairment of small airways
was seen during the early stages of mycoplasmal pneumonia. The change of maxi-
mum mid-expiratory flow (MMF) was similar to that of V25/HT. The MMF value
was lowest five to six days after onset and then it gradually returned to normal.
Based on the FEV 1.0 percent, V50/HT, V25/HT, and MMF data, lung function
impairment in patients with mycoplasmal pneumonia involved both the high and
low lung volumes.
Complicating Infections
Mixed infections due to H. influenzae, M. pneumoniae, and S. aureus occurred in
27 adults with mycoplasmal pneumonia. Respiratory viruses were also responsible
for other mixed infections. In a different study, influenza virus, parainfluenza virus,
respiratory syncytial virus, and adenovirus were diagnosed in children with
mycoplasmal pneumonia.
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Chemotherapy
The clinical effectiveness of various antibiotics for treatment in children and
adults with mycoplasmal pneumonia was also examined. Efficacy was based on
reduction in the duration of fever and cough and in the resolution of chest roent-
genography. The mean duration of fever was 2.6 days in patients treated with
macrolides, 2.3 days with tetracyclines, 3.2 days with aminoglycosides, 4.8 days with
penicillins, and 5.5 days with the cephemes.
The duration of fever in patients treated with the penicillins and cephemes were
similar to that of the untreated control group. The mean duration of cough in pa-
tients treated with macrolides was 10.2 days and was 9.0 days for either the
tetracyclines or the aminoglycosides (Table 1). Improvement of disease shown by
chest X-ray (90 percent resolution) occurred in 49.8 percent ofthe patients one week
after treatment with macrolides and in 87.0 percent of the patients after two weeks
of treatment. Following tetracycline therapy, 26.4 percent of the patients improved
after one week and 73.3 percent after two weeks. The aminoglycosides produced im-
provement in 94.7 percent of the patients at the end of two weeks of treatment. The
improvement rate among patients given the penicillins or cephemes was less than 50
percent after two weeks of treatment. Treatment with the tetracyclines markedly
reduced or eliminated colonization of the mycoplasma from the respiratory tract
within the first week, whereas colonization persisted a little longer in patients given
the microlides.
DISCUSSION
Mycoplasmapneumoniae disease commonly occurs in children and young adults
[1,2,3,4] but has also been reported in older subjects [2,5]. In our study, we ex-
amined over the past 17 years 221 patients, aged 15 to 82, with mycoplasmal
pneumonia. During this time we noted periodic epidemic peaks every three to four
years. Each epidemic period continued for six to eight months. These epidemic
peaks were also noted by Lind [13] and Ponka [12]. There was no seasonal variation
in the incidence of disease in our study. A persistent cough, which occurred
throughout the night and lasted three to four weeks, was the most characteristic
feature of the disease. Other features were fever, rales, headache, sputum ejection,
and dyspnea. Myringitis was seen in only a few of the adult patients. Patients with
non-mycoplasmal but atypical pneumonias presented with coryzal symptoms, sore
throat, and chills in our study.
Chest X-ray examination did not reveal any special specific or pathognomic
features [2,3,12]. X-ray shadows were predominantly ofthe alveolar pattern or were
mixed with interstitial patterns of disease in our study. Rosmus et al. [14] reported
the development of roentgenographic findings in mycoplasma pneumonia which
were characterized by a diffuse reticular pattern, followed by acinar involvement,
and finally by a return to a reticular, interstitial pattern. There was very little change
in the patterns ofroentgenography during the time course ofinfection. A pleural ef-
fusion pattern was seen in 17 cases and an atelectatic pattern in three cases. Shadows
occurred most frequently in the lower fields, in the frontal regions ofsegments 4 and
5 and in segment 10. In all cases, it was important to discriminate between mycoplas-
mal pneumonia and other respiratory diseases. Differential diagnosis for pulmonary
tuberculosis was especially difficult and required particular caution.
It has been shown previously that mycoplasma infections impair the function of
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ciliated epithelial cells and produce inflammation of airways spreading to
respiratory bronchioles [2,3,10,15]. We have shown that lung function was impaired
both at high and at low lung volume based on significant reduction in V50/HT,
V25/HT, and MMF values. These results reflect the pathologic alteration of the
small airways [7].
Most M. pneumoniae infections show a mild course. However, at times, infec-
tions can cause severe sequelae involving the liver, pancreas, or central nervous
system, or infections can be complicated by secondary infections with other
bacterial or viral agents [2,3,4,16]. Moreover, the agents can persist for long
periods. Therefore, it is important to carry out proper therapy ofM. pneumoniaein-
fections. In our study, the tetracycline therapy was the most effective in reducing
colonization and clinical disease, whereas the macrolides were more effective in res-
olution of roentgenographic manifestations.
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